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Abstract
Acute myeloid leukemia (AML) is a heterogenous disorder that results from a block in the
differentiation of hematopoietic progenitor cells along with uncontrolled proliferation. In
approximately 60% of cases, specific recurrent chromosomal aberrations can be identified by
modern cytogenetic techniques. This cytogenetic information is the single most important tool to
classify patients at their initial diagnosis into three prognostic categories: favorable, intermediate,
and poor risk. Currently, favorable risk AML patients are usually treated with contemporary
chemotherapy while poor risk AML patients receive allogeneic stem cell transplantation if suitable
stem cell donors exist. The largest subgroup of AML patients (~40%) have no identifiable
cytogenetic abnormalities and are classified as intermediate risk. The optimal therapeutic strategies
for these patients are still largely unclear. Recently, it is becoming increasingly evident that it is
possible to identify a subgroup of poorer risk patients among those with normal cytogenic AML
(NC-AML). Molecular risk stratification for NC-AML patients may be possible due to mutations of
NPM1, FLT3, MLL, and CEBPα as well as alterations in expression levels of BAALC, MN1, ERG,
and AF1q. Further prospective studies are needed to confirm if poorer risk NC-AML patients have
improved clinical outcomes after more aggressive therapy.
Introduction
Acute Myeloid Leukemia (AML) is a broad range of disor-
ders that are all characterized by an arrest of maturation
along with uncontrollable proliferation of hematopoietic
progenitor cells. The French-American-British classifica-
tion is still widely used in clinical setting that groups AML
into 8 subgroups (M0-M7) based on its degree of differen-
tiation and morphology. Due to the heterogenous nature
of AML even within specific FAB subtypes, there is a highly
variable prognosis among AML patients. The overall 5-
year survival rate for AML is still less than 50% in adults
and significantly lower in the elderly [1]. The median sur-
vival in patients over the age of 65 is less than one year
and only 20% of these patients survive two years [2].
Treatment for all subtypes of AML, except the M3 subtype,
involves combination chemotherapy and a possible
hematopoietic stem cell transplant as part of consolida-
tion therapy. Acute Promyelocytic Leukemia (APL, M3
subtype) is treated with a combination of the differentia-
tion-inducing agent all-trans retinoic acid and chemother-
apy resulting in the presumed cure of 75–85% of patients
[3]. In general, the prognosis of patients with AML is cur-
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rently based upon the presence or absence of cytogenetic
abnormalities and is divided into favorable, intermediate
and unfavorable subgroups (see table 1) [4]. There is het-
erogeneity within these subgroups, especially the interme-
diate subgroup, and the age of the patient is also an
important prognostic factor. One study estimated the 5
year overall survival (OS) of the favorable subgroup at
55%, the intermediate subgroup at 38% and the unfavo-
rable subgroup at 11% [5]. Patients who have the follow-
ing cytogenetic abnormalities: inv(16), t(15;17) (the
translocation found in APL), or t(8;21) have a favorable
prognosis while patients with several other cytogenetic
abnormalities including monosomy 5, monosomy 7,
11q23, and complex cytogenetics may have a poor prog-
nosis. However, approximately 40% of AML patients have
no identifiable cytogenetic abnormality by using modern
cytogenetic and fluorescence in-situ hybridization (FISH)
methods. These patients are usually classified as an inter-
mediate risk group. Although the NC-AML patients are
currently considered as having an intermediate prognosis,
these patients have a wide range of overall survival rates
between 24% to 42%. Recently, multiple institutions
from Europe and the United States conducted retrospec-
tive studies which showed some molecular markers that
could identify good and poor risk NC-AML patients and
suggest that these patients should be treated accordingly.
This review encompasses a discussion of the molecular
markers in NC-AML which are mutations (NPM1, FLT3,
MLL-PTD, CEPBα) and those that are a function of over-
expression (BAALC, MN1, ERG-1, AF1q). These differ-
ences in markers of mutation versus over-expression are
summarized in Table 1. Furthermore, some of the genetic
abnormalities have also been found to be useful for min-
imum residual disease monitoring and as potential thera-
peutic targets.
The Nucleophosmin Gene (NPM1)
Mutations of NPM1 have recently been described as one
of the most frequent genetic lesions in AML, occurring in
50–60% of adult AML with normal karyotype [6,7]. Addi-
tional evaluation has shown that mutations in NPM1 are
rare in other risk groups of AML and in one study, no
NPM1 mutations were shown in patients with favorable
cytogenetics [7]. The NPM1 gene encodes a nucleo-cyto-
plasmic shuttling protein that regulates the ARF-p53
tumor-supressor pathway [8,9]. Mutations in this gene
result in an abnormal accumulation of the NPM1 protein
in cytoplasm. Two types of mutations have been described
to date. The first and most frequent mutations consists of
a 4-nucleotide (nt) insertion (YWTG; YUPAC code)
downstream from nucleotide 959; the second is deletion
of a GGAGG sequence at positions 965 through 969 and
substitution with 9 extra nt (GenBank accession no.
NM_002520). Both mutations lead to aberrant cytoplas-
mic localization of NPM1 as shown after immunostaining
with anti-NPM1 monoclonal antibodies. This is caused by
open reading frameshift mutations that lead to either the
disruption of the NPM1 nucleolar-localization signal or
the generation of a leucine-rich nuclear export motif. In
all mutated cases, the resulting frameshift led to a product
five amino acids longer with the new C-terminal tail
CFSQVSLRK, peculiar to the NPM1-mutated product [7].
Recent studies in cell lines and knockout mice have
shown that NPM1 is involved in the control of genomic
stability and contributes to growth-suppressing pathways
through its interaction with ARF. Therefore, the loss of
NPM1 expression can contribute to tumorgenesis [10].
Several methods are suitable for detecting NPM1 gene
mutation, including molecular and immunohistochemi-
cal studies [7,11-13].
NPM1 gene mutations appear to occur more frequently in
adult female AML patients [14-16] and also tend to be
associated with: a) higher white blood cell count, b)
monocytic differentiation (in particular FAB M5b AML
subtype) [17], c) wide morphologic spectrum, d) multi-
lineage involvement [9], e) lack of CD34/CD34-negativity
[7,9,11], f) normal cytogenetics [18], g) a decreased prev-
alence of CEBPα mutations [17], h) high frequency of
FLT3-ITD gene mutation [18] and i) a trend toward favo-
rable clinical outcome, especially in patients without a
FLT3 gene mutation [7,15]. Patients with only an NPM1
mutation exhibit higher complete remission (CR) and sig-
nificantly better OS [14-16], event free survival (EFS) [15],
and disease free survival (DFS) as well as a lower cumula-
tive incidence of relapse [6,16]. The various study out-
comes of risk associated with NPM1 status are
summarized in Table 2.
Detection of NPM1 gene mutations may be useful in the
dissection of the heterogeneous group of AML patients
Table 1: Genetic Abnormalities in Normal Cytogenetic AML
Name Prognosis Prevalence Expression
NPM-1 Favorable 50–60% Mutation
FLT3-ITD Unfavorable 30–40% Mutation
FLT3-Asp835 Unclear 5–10% Mutation
BAALC Unfavorable 65.7% Over expression
MN1 Unfavorable 50% Over expression
MLL-PTD Unfavorable 7.7% Mutation/over expression
CEBPα Favorable 15–20% Mutation
ERG-1 Unfavorable 25% Over expression
AF1q Unfavorable 75% Over expressionJournal of Hematology & Oncology 2009, 2:23 http://www.jhoonline.org/content/2/1/23
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with normal karyotype into prognostically different sub-
groups [7]. Further, due to their frequency and stability,
NPM1 mutations may become a new tool for monitoring
minimal residual disease in AML-patients with a normal
karyotype [9].
The Fms-like tyrosine kinase 3 Gene (FLT3)
FLT3 is a tyrosine kinase that is primarily expressed on
hematopoietic progenitor cells and functions in the pro-
liferation and differentiation of these cells. FLT3 is the
most commonly mutated gene in AML with the mutation
occurring in approximately 30–40% of AML patients [19].
The most common mutation consists of an internal tan-
dem duplication (FLT3-ITD) in the juxtamembrane
domain of the FLT3 gene. FLT3-ITD results in a constitu-
tively active FLT3 protein that promotes Stat 5 phosphor-
ylation. The net consequence of FLT3/Stat5 constitutive
activation is uncontrolled hematopoietic cell prolifera-
tion [20]. AML patients who carry the FLT3-ITD mutation
appear to have poorer clinical outcomes. Adult patients
usually have a higher prevalence of FLT3-ITD than pediat-
ric AML patients. This observation may partially explain
why adult AML has a poorer clinical outcome than pedi-
atric AML. Clinically, AML patients with FLT3-ITD tend to
Table 2: NPM1 Mutant Risk Assessment
Study Number of NPM1 mutants/
total cases studied
Treatment Demographics of those 
patients with NMP1 
mutations
+ NPM1 mutant assessment 
of risk
Verhaak, et al [6] 95/275
(34.5%)
Dutch Belgian Hematology 
Oncology Cooperative Groop 
(HOVON) protocols
- Median age 47 yo
- 60% of those with FLT3 
ITD
- decreased in those age < 
35 yo
- 42% of those with WBC 
>20 K
HR
EFS 1.96
DFS 2.0
OS 2.13
Döhner, et al [14] 145/300
(48.3%)
AML Study Group (AMLSG)
AML HD93
AML HD98-A
- Increased in M4/M5
- extramedullary LAD
- Female predominance
- Decreased CD34 antigen 
expression
- Increased LDH
- Associated with FLT3 ITD
- WBC >20 K
- Increased bone marrow 
blast counts
Odds ratio (OR) after 
induction
CR 2.81
Schnittger, et al [15] 212/401
(52.9%)
German AMLCG99 study - Associated with FLT3 ITD
- Without FLT3, OS and EFS 
increased
- Female predominance
Relative risk (RR)
EFS 0.527
Theide, et al [16] 408/1485
(27.5%)
Deutsche Studieninitiative 
Leukämie (DSIL) AML 96 
protocol
- High bone marrow blasts
- Female predominance
- WBC >20 K
- Association with FLT3-ITD 
mutations
OR
OS 0.76
DFS 0.66
Boissel, et al [17] 50/106
(47%)
French Leukemia French 
Association (ALFA)
ALFA90
ALFA9802
- Increased in FAB M4/M5
- 25% with FLT3-ITD
- Decreased CEBPA
- WBC >20 K
No difference in CR or long 
term outcomes
Suzuki, et al [18] 64/257
(24.9%)
Japan Adult Leukemia Study 
Group protocols
- Associated with FLT3-ITD - NPM1 mutant unfavorable 
factor for relapse
OR 2.106
- NPM1 wild type 
unfavorable for CR
OR 4.908
-NPM1 mutant with FLT3-
ITD favorable for CR
OR 20.8Journal of Hematology & Oncology 2009, 2:23 http://www.jhoonline.org/content/2/1/23
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have higher WBC counts and an increase percentage of
leukemic blasts [21]. A missense mutation in the activa-
tion loop (FLT3-ALM) of the second tyrosine kinase
domain of FLT3 at Asp835 leads to another common FLT3
mutant (FLT3-TKD) that is found in approximately 5–
10% of AML patients [22]. Although the clinical signifi-
cance of this FLT3 mutation especially in NC-AML is not
yet clear, several studies indicate that it is also an adverse
prognostic indicator [19,21]. The associated risk of FLT3
status determined by these studies are summarized in
Table 3.
Particularly in AML patients with normal cytogenetics,
FLT3-ITD status is important in assessing the prognosis of
patients. Several studies have demonstrated that FLT3-ITD
in NC-AML patients correlates with an adverse prognosis
for both DFS and OS [23-25]. Not only does the presence
of FLT3-ITD impart a poor prognosis, but the size of the
internal tandem duplication is significant. The duplica-
tion can range in size from three to hundreds of nucle-
otides and longer duplications correlate with a worse OS
[26]. In addition to the mutant allele, the status of the
wild-type allele in patients with FLT3-ITD has been dem-
onstrated to have prognostic significance. Patients who
lack the wild-type allele have a worse prognosis [27]. In
those who express the wild-type allele, the ratio of the
mutant to wild-type level of FLT3-ITD has a strong corre-
lation to survival. In one study, patients with a high
mutant to wild-type ratio (defined as greater than 0.78)
had a significantly shorter OS and DFS than those with a
Table 3: Positive FLT3-ITD Risk Assessment
Study Number of FLT3 mutants/
total cases studied
Treatment Demographics of those 
patients with FLT3-ITD
+ FLT3-ITD assessment of 
risk
Fröhling, et al [21] 119/523 all comers
(22.8%)
71/224 NC AML
(32%)
AML Study Group (AMLSG)
AML HD93
AML HD98-A
- Associated with high WBC
- Associated with de novo 
AML
- Increased bone marrow and 
peripheral blood blasts
- Increased LDH
Hazard ratio (HR)
Remission duration
2.35
Kainz, et al
[23]
26/100
(26%)
16/53 NC AML
(30%)
Various protocols - Increased in M4 (50%)
- Increased LDH
- WBC >10 K
OR
CR 0.31
Relapse rate 8.3
OS 0.17
Ciolli, et al
[24]
25/100
(25%)
Various protocols - WBC > 30 K
- Decreased incidence of 
secondary AML
- Female predominance
- Increased LDH
HR
RFS 3.1
Post remission survival 2.1
Stirewelt, et al [26] 48/151
(31.8%)
Southwest Oncology Group
SWOG 9333
SWOG 9500
- High bone marrow blasts
- High peripheral blood blasts
- WBC >30 K
HR
OS 1.35
RFS 1.7
Whitman, et al [27] 23/82
(28%)
CALGB protocol - All patients evaluated had 
NC AML, age <60, and de 
novo AML
- Median age 37 yo
- N = 8 FLT3ITD/-
No clear evidence in 
difference between groups, 
but trend towards decreased 
OS with FLT3ITD/-
Thiede, et al [28] 200/979
(20.4%)
Various protocols - Increased in M5
- WBC >50 K
- Increased bone marrow 
blasts
OR
Mut/wt ratio 1
- all ages
OS 1.8
DFS 3.2
- age < 60
DFS 4.2
Mut/wt ratio 2
- all ages
OS 2.8
DFS 8
- age < 60
DFS6.9Journal of Hematology & Oncology 2009, 2:23 http://www.jhoonline.org/content/2/1/23
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lower ratio. The DFS and OS for patients with a lower ratio
were no different than the group of patients without FLT3
abnormalities [28].
In addition to mutation of FLT3 and the decreased expres-
sion of the wild-type allele, over-expression of FLT3 in the
absence of mutation has also been observed in AML
patients. Over-expression of FLT3 even in the absence of
FLT3-ITD is also an unfavorable prognostic factor for OS
[29]. As FLT3-ITD is an adverse prognostic factor, it has
been speculated that patients with this genetic abnormal-
ity should be considered for more intensive therapy. How-
ever, a large study of 1135 adult patients with AML
including 25% with FLT3-ITD, there was no improvement
in outcome based upon whether or not a patient with
FLT3-ITD received a transplant in first complete remission
[30].
The association of FLT3 mutations have also been evalu-
ated in patients with favorable cytogenetics (t(8;21),
inv16, t(15;17)). FLT3 mutations were noted in 15 of 17
patients studied. Of these patients, 41% of those with
t(15;17) were associated with FLT3 mutations and only
9% of cases with inv16. Those with PML-RARα had
decreased to no CD11c or HLA-DR expression. However,
this study did not illustrate significant correlations with
outcomes and FLT3 mutational status [31].
As FLT3 mutations lead to constitutively activated signal-
ing, much work has been performed to develop small
molecule FLT3 inhibitors. Unfortunately FLT3 inhibitors
have thus far shown disappointing results as remission
induction has been short lived. Nevertheless, there is opti-
mism that FLT3 inhibitors may be more efficacious when
used in combination therapies [32]. Besides being a useful
as a prognostic marker and a therapeutic target, FLT3-ITD
has also been used for minimal residual disease monitor-
ing [33].
The mixed lineage leukemia gene (MLL)
MLL is frequently rearranged in AML and ALL and has
been found in combination with greater than 30 different
genes. The most frequent rearrangements in the current
published series were unbalanced translocations leading
to loss of chromosomal material. Overall, loss of 5q and/
or 7q chromosomal material seemed the more common
event, and losses of 5q, 7q, and 17p in combination were
observed in many cases. Overrepresented chromosomal
material from 8q, 11q23, 21q, and 22q was found recur-
rently and in several cases this was due to the amplifica-
tion of the MLL (located at 11q23) and AML1/RUNX1
(located at 22q22) genes [34]. MLL encodes a histone
methyltransferase that plays a role in hematopoiesis by
regulating homeobox genes. In mice heterozygous for
MLL, both hematopoietic abnormalities are found as well
as decreased Hox gene expression [35].
In addition to rearrangements, the MLL gene can also
undergo partial tandem duplications of exons 5–11 or
exons 5–12 and produce an elongated protein. This
abnormal protein, which contains a DNA-binding and
transcriptional repression domain, can suppress the
expression of the wild-type allele by an unknown mecha-
nism. Interestingly, the silencing of wild-type MLL in
blasts positive for MLL-PTD was reversed by DNA methyl-
transferase and histone deacetylase inhibitors [36]. These
findings indicate the potential therapeutic role of the
DNA methyltransferase and histone deacetylase inhibi-
tors such as decitabine and valpoic acid in these AML
patients.
In one large study of 247 young adult patients with AML,
MLL-PTD was found in 7.7% of patients. In this study,
MLL-PTD was an adverse prognostic indicator as the
median remission duration was 19 months in the absence
of MLL-PTD and 7.75 months in its presence [37]. In gen-
eral, the majority of studies indicate that MLL-PTD is poor
prognostic indicator in NC-AML including median sur-
vival and relapse-free interval [38]. Additionally, the use
of MLL-PTD for minimal residual disease monitoring has
been shown to be effective in detecting relapse prior to
clinical manifestations [39].
The CCAT/Enhancer Binding Protein Alpha Gene (CEBPα)
CEBPα is an essential transcription factor for granulocytic
differentiation as demonstrated by CEBPα-null mice that
lack mature granulocytes [40,41]. Studies have reported
N- and C-terminal CEBPα mutations in approximately
15% to 20% of AML [42]. The mutant proteins act in a
dominant-negative manner to block DNA binding and
transactivation of granulocyte target genes resulting in the
failure of granulocytic differentiation [40]. Patients with a
CEBPα mutation have higher hemoglobin levels, lower
platelet counts, higher blast counts, and are less likely to
present with lymphadenopathy or extramedullary leuke-
mia compared to patients without a CEBPα mutation.
Suprisingly, as CEBPα is required for differentiation,
mutation of CEBPα is correlated with beneficial effects on
remission, CR duration [42], event-free survival [17], DFS
[25], and OS [41]. While there is no significant difference
in CR rates between patients with and without CEBPα
mutations [25,42], mutations are associated with a signif-
icantly reduced hazard ratio for death and event free sur-
vival [41]. CEBPα mutations appear to be an independent
prognostic factor even in the presence of FLT3 and MLL
mutations. Studies have shown that there is no significant
overlap between the patients with CEBPα mutation and
patients with FLT3-ITD or MLL-PTD mutations, suggest-
ing that CEBPα mutations define a distinct biologic sub-
class of NC-AML [42]. CEBPα mutation is an independent
prognostic marker for OS irrespective of age, MLL-PTD,
and FLT3-ITD status [43] and is another marker that per-Journal of Hematology & Oncology 2009, 2:23 http://www.jhoonline.org/content/2/1/23
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mits the division of NC-AML into distinct clinical groups
[25].
While NPM1, FLT3, MLL-PTD, CEPBα are all mutations
noted in NC-AML, additional genetic abnormalities are
noted in the form of over-expression. More detailed dis-
cussion of BAALC, MN1, ERG-1, and AF1q give insight to
over-expression of genes in NC-AML.
The Brain and Acute Leukemia Cytoplasmic (BAALC)
BAALC has also been found to be an important adverse
prognostic factor in NC-AML. Though little is known
about the biological function of BAALC, it is highly
expressed in hematopoietic precursor cells as well as
leukemic blasts and is down-regulated during differentia-
tion. BAALC has been postulated to function in the
cytoskeleton network due to its cellular location [44,45].
Several studies have demonstrated that high BAALC
expression is a poor prognostic indicator in NC-AML for
such factors as OS, DFS, and resistant disease [46,47]. In
one study of 86 AML patients with NC-AML, high expres-
sion of BAALC was found to be an independent risk factor
for both inferior OS (1.7 vs. 5.8 years) and DFS (1.4 vs 7.3
years). Different post-remission strategies among patients
with different level of BAALC expression (consolidation,
autologous and allogeneic stem cell transplantation) have
no influence on OS. However, high BAALC expressive
patients who underwent allogeneic stem cell transplanta-
tion have lower cumulative relapse rate compared to
those who underwent autologous stem cell transplanta-
tion [47].
Meningioma 1 (MN1)
MN1 is an oncoprotein that has been found to function as
a transcription coactivator. In AML it has been found as
part of the translocation t(12;22)(p13;q11) which leads
to the MN1-TEL fusion gene [48]. In animal models, the
MN1-TEL fusion gene collaborates with HOXA9 to induce
AML [49]. Recently, high levels of expression of MN1 have
been found to be a prognostic marker in NC-AML.
Though the exact function of MN1 in hematopoietic cells
is unclear, it is another protein that is highly expressed in
hematopoietic cells and is down-regulated during differ-
entiation. In a study of 142 adult patients with NC-AML,
high MN1 expression was significantly related to unmu-
tated NPM1, poor response to initial induction chemo-
therapy, high relapse rate, risk free survival, and OS. In
multivariate analysis, high MN1 expression was an inde-
pendent prognostic marker [50].
The ETS-related gene (ERG)
ERG is a member of the ETS family of transcription fac-
tors. High ERG expression is associated with the upregula-
tion of many genes which are involved in cell
proliferation, differentiation, and apoptosis [51]. The
ERG gene is a recently identified molecular marker pre-
dicting adverse outcome of NC-AML patients. Over-
expression of the ERG gene was first discovered in patients
with complex karyotypes and abnormal chromosome 21
[34,52]. Marcucci, et al showed that in patients less than
60 years old with de novo NC-AML, those patients
expressing the highest levels of ERG (the top 25%) have a
worse cumulative incidence of relapse (CIR) and OS. In
this analysis, ERG over-expression predicted a shorter sur-
vival only in patients with low BAALC expression. Though
more study is needed to confirm these results, ERG over-
expression in NC-AML not only predicts an adverse clini-
cal outcome, but also appears to be associated with a spe-
cific molecular signature [51].
As the ERG gene is located on chromosome 21, it has been
speculated that ERG expression may play a role in the
pathogenesis of acute leukemia in patients with Down's
syndrome. Patients with Down's syndrome are known to
have a higher incidence of acute leukemia [53]. The high
ERG expression may also be related to acute megakaryob-
lastic leukemia (FAB-M7) which is associated with tri-
somy 21 [54].
AF1q expression
Two small studies conducted by Tse et al suggest that ele-
vated AF1q expression is associated with poor outcomes
both in pediatric AML and adult myelodysplastic syn-
drome (MDS) [55,56]. In the pediatric study, AF1q
expression in AML patients varied from 0 to 154-fold
compared with normal marrow and increasing AF1q
expression level was associated with worsening survival
with a hazard ratio of 1.02 per fold in AF1q expression (p
= 0.032). High AF1q expression was related to poor sur-
vival in univariate and multivariate models without asso-
ciation with any specific adverse cytogenetics [55]. The
AF1q expression levels in the MDS study (total of 47
patients) suggested a statistically significant correlation
with IPSS and AF1q expression level in high risk MDS
[56]. Consistent with the findings in the pediatric AML
study, MDS patients with high AF1q expression have an
increased hazard ratio of death from MDS and relapse
after allogeneic stem cell transplantation with correlation
of specific poor cytogenetics. These observations led to a
hypothesis that elevated AF1q expression might serve an
adverse molecular marker for poor prognosis in AML
patients with normal cytogenetics.
Recently, Strunk et al examined AF1q expression in 290
adult NC-AML patients (aged < 60). They found NC-AML
patients with low AF1q expression (AF1qlow) had better
OS (p = 0.026) and CR rate with initial induction chemo-
therapy (p = 0.06) compared to high AF1q expressing
patients (AF1qhigh). The AF1qhigh patients had a signifi-
cantly greater incidence of concurrent FLT3-ITD. A sub-Journal of Hematology & Oncology 2009, 2:23 http://www.jhoonline.org/content/2/1/23
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group of the AF1qhigh patients who received allogeneic
stem cell transplantation (SCT) had a significant better
relapse-free survival compared to patients who received
chemotherapy/autologous SCT (p = 0.04). This suggests
that high AF1q expression is a poor prognostic marker for
adult NC-AML patients and may help direct post-induc-
tion treatment strategies.
Gene expression Profiling
Normal cytogenetics are detected pretreatment in approx-
imately 45% of patients with de novo acute myeloid
leukemia; thus, this constitutes the single largest cytoge-
netic group of AML. Recently, molecular genetic altera-
tions with prognostic significance have been reported in
these patients. They include internal tandem duplication
of the FLT3 gene, partial tandem duplication of the MLL
gene, mutations of the CEBPα and NPM1 genes and aber-
rant expression of the BAALC, ERG and MN1 genes. Addi-
tionally, gene-expression profiling has been applied to
identify prognostically relevant subgroups [57].
Gene expression studies have identified that the majority
of NC-AML patients fall into specific clusters that exhibit
similar gene expression profiles. The identification of
these clusters may not only be useful for diagnostic pur-
poses, but also may help guide prognosis and therapeutic
approaches. For example, NC-AML patients were found to
up-regulate class I homeobox A and B gene families [58].
In another study, DNA microarray experiments identified
two distinct subgroups of NC-AML including one that was
closely related to the gene signatures observed in AML
with translocations. In this study, NC-AML patients in the
"translocation-like" group had a superior prognosis to the
other group [57]. Similarly, a separate study also found
two distinct gene expression clusters in NC-AML patients
with significantly different survival. Using a panel of 133
genes, it was possible to predict the clinical outcome of
NC-AML patients [59]. NC-AML patients in the cluster
with worse survival were more likely to harbor FLT3 muta-
tions and were more commonly diagnosed with specific
AML subtypes (FAB M1 and M2). Bullinger's observation
was recently validated by a Cancer and Leukemia Group B
(CALGB) study that used a different microarray platform
and had a longer follow up [60]. Gene-expression profil-
ing allows a comprehensive classification of AML that
includes previously identified genetically defined sub-
groups and a novel cluster with an adverse prognosis [59].
In the future, gene expression profiling studies will likely
play a role clinically in molecularly risk stratifying NC-
AML patients as well as further elucidating the biology of
NC-AML.
Minimal Residual Disease
Minimal residual disease (MRD) can provide an early
indication of potential relapse in AML post-treatment.
There has been some initial evaluation of the utility of
FLT3-ITD, CEBPα, ERG, NPM1, and MLL in MRD whereas
AF1q, MN-1, and BAALC have not. The impact of FLT3
was analyzed in 11 patients. All of the six patients with
positive quantitative real-time polymerase chain reaction
(RQ-PCR) post-treatment eventually relapsed [33]. Real-
time quantitative PCR has also been used to evaluate
MRD in patients carrying NPM1 mutations at time of
diagnosis. Decreasing NPM1 copy number correlated
with response to therapy and in four cases followed post-
therapy, rising copy number preceded hematological
relapse [13]. Additional evaluation in the post-transplant
setting showed that all patients who remained NPM1
mutant positive after transplant relapsed and all those
who had increases in mutation copies post-transplant
relapsed as well [61]. Comparison of CEBPα mutational
status between diagnosis and relapse in AML was first
investigated by Tiesmeier et al [62]. Two of 26 patients
that relapsed had mutated CEBPα which persistent post-
treatment suggesting a concordance between presentation
and relapse. As approximately 60% of CEBPα mutations
are insertion or deletions, they are an amenable to MRD
monitoring by RQ-PCR [63]. One case study have also
reported the utility of RT-PCR for detecting ERG MRD.
The patient had a negative ERG fusion gene after trans-
plant which then recurred at time of relapse [64]. A larger
analysis of 19 patients conducted by Kong et al. noted
four types of TLS/FUS-ERG chimeric transcripts via RT-
PCR. The transcripts were detectable at diagnosis as well as
during remission and relapse suggesting resistance to con-
ventional chemotherapy [65]. Finally, RT-PCR has also
been used to evaluate expression levels of partial tandem
duplications in the MLL gene. Expression levels in 16
patients were analyzed at time of diagnosis and at relapse
and found to be equivalent. Additionally, molecular
relapse was detected 35 days before clinical relapse in two
patients [39]. Thus, MLL-PTD was suggested as a target for
MRD detection. Currently, MRD monitoring via these
molecular markers is not commercially available to the
community physician, but these studies provide insight to
their future potential in MRD monitoring.
Conclusion
Though NC-AML comprises the single largest subgroup of
AML, these patients pose considerable challenges in diag-
nosis, risk stratification, and post-treatment monitoring
for minimal residual disease. Gene expression and profil-
ing studies have shown that NC-AML is very heterogene-
ous at the molecular level. Multiple studies have shown
that NC-AML patients usually exhibit two or more genetic
aberrations. While assessment of these molecular prog-
nostic markers is not widely available to the community
physician outside of a clinical trial, future studies will help
to further validate the prognostic importance of these
altered genetic abnormalities in systemic multivariateJournal of Hematology & Oncology 2009, 2:23 http://www.jhoonline.org/content/2/1/23
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analysis in the NC-AML patients. Once the prognostic
importance of these genetic abnormalities is clear, it may
be possible to appropriately tailor the aggressiveness of
therapy to NC-AML patients. Further, these studies also
have the potential to identify novel therapeutic targets
that may be used to design targeted therapies. In the
future, specific genetic abnormalities may be profiled in
AML patients in a similar manner to the immunopheno-
typing that is currently done by flow cytometry to obtain
information on accurate diagnosis, prognosis, and disease
monitoring.
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